Retinal haemorrhage (reporting odds ratio [ROR] 10.36, 95% confidence interval [95% CI] 2.65#40.50; p <0.001), blindness (ROR 3.73, 95% CI 1.08#12.96; p = 0.04) and uveitis (ROR 6.91, 95% CI 1.64#29.13; p = 0.01) were significantly more frequently reported for aflibercept than for bevacizumab and ranibizumab.